Core Viewpoint - The article discusses the evolution of the "Hallmarks of Cancer" theory, expanding from six to nine characteristics and introducing four dimensions to better understand cancer complexity [2][3]. Group 1: Evolution of Cancer Characteristics - In 2000, Douglas Hanahan and Robert Weinberg first proposed six hallmarks of cancer: sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis [5]. - In 2011, two additional hallmarks were added: deregulating cellular energetics and escaping immune destruction. By 2022, the ninth hallmark, "unlocking phenotypic plasticity," was introduced [6]. Group 2: Nine Hallmarks of Cancer - The newly added ninth hallmark refers to cancer cells' ability to change their identity and characteristics, explaining the diversity of cell types within tumors and their adaptability to treatment pressures [9]. Group 3: Four Dimensions of Cancer Complexity - The new framework categorizes cancer complexity into four dimensions: 1. The nine hallmarks themselves, which are core capabilities for cancer cell survival and development [11]. 2. Five enabling characteristics, including genomic instability, tumor-promoting inflammation, neural regulation, polymorphic microbiome, and non-mutational epigenetic reprogramming, which facilitate the acquisition of the nine hallmarks [12]. 3. Various cells in the tumor microenvironment, such as cancer cells, senescent cells, cancer-associated fibroblasts, neurons, endothelial cells, and immune cells, which assist cancer cells in acquiring necessary features [12]. 4. Systemic interactions, highlighting cancer as a systemic disease interacting with other parts of the body [13]. Group 4: Focus on Neural Regulation - "Cancer neuroscience" has emerged as a significant area of focus, revealing that nerves not only surround tumors but also communicate closely with cancer cells. In some cases, cancer cells form "synapse-like" connections with nerves, receiving growth signals through neurotransmitters [20][21]. Group 5: Microbiome's Role in Cancer - The microbiome, consisting of bacteria, fungi, and viruses, has a profound impact on cancer. The composition of an individual's microbiome can influence cancer development and treatment responses [22][23]. - The gut microbiome may affect the efficacy of cancer immunotherapy by modulating the immune system. Studies indicate that fecal transplants from responding patients can enhance treatment effects in non-responders [24][25]. Group 6: Future Directions in Cancer Treatment - Scientists propose a "feature-coordinated targeting" treatment strategy, aiming to target multiple cancer characteristics simultaneously to prevent the emergence of resistance mechanisms [26]. - Successful clinical examples include combinations of anti-angiogenic drugs with immune checkpoint inhibitors showing superior effects in certain cancers. Future treatments may involve combinations targeting different cancer features, guided by advancements in single-cell sequencing and spatial transcriptomics [30][31].

Group 1: Core Insights - Jiangbei New District in Nanjing has evolved into a national-level innovation hub, recognized for its significant contributions to the biopharmaceutical industry and technology advancements [1][2] - The district is home to over 1,300 biopharmaceutical companies and more than 200 new drugs in development, positioning it as a key player in Jiangsu's biopharmaceutical sector [2][4] - Notable achievements include the first CAR-T drug for cross-border supply by Reindeer Biotech and the first nucleic acid drug ER2001 injection by Aima Biotech, showcasing the district's innovative capabilities [2][3] Group 2: Industry Developments - Jiangbei New District has established itself as a center for integrated circuit industries, hosting hundreds of related companies, including TSMC, and covering the entire supply chain from design to manufacturing [3][4] - The district has seen significant investments in biopharmaceuticals, with funds supporting companies like Vili Biotech, which has 14 innovative drug candidates, and the recent approval of new antiviral drugs [5][6] - The collaboration between Nanjing University and Jiangbei New District aims to foster talent and innovation in biopharmaceuticals, with plans to accommodate over 5,000 students and faculty [4][5] Group 3: Community and Infrastructure - The district is characterized by a high concentration of PhD holders, with over 30% of the local population in the Longshan community holding advanced degrees, contributing to a vibrant innovation ecosystem [6][7] - The establishment of Nanjing North Station as a major transportation hub is expected to enhance connectivity and attract resources, further supporting the district's growth as a technology and innovation center [8][9] - Jiangbei New District is committed to creating a comprehensive ecosystem that integrates education, research, industry, and application in the biopharmaceutical sector [5][6]

Core Insights - Jiangbei New Area in Nanjing has evolved into a national-level innovation hub, particularly in the biopharmaceutical and semiconductor industries, showcasing significant technological advancements and industry breakthroughs [1][2][3]. Biopharmaceutical Industry - Jiangbei New Area is designated as a key area for developing a world-class biopharmaceutical industry cluster, with over 200 new drugs under research and more than 1,300 biopharmaceutical companies [1][2]. - Notable achievements include the first CAR-T drug for cross-border supply by Reindeer Biotech and the first nucleic acid drug ER2001 injection by Aima Biotech, highlighting the area's innovative capabilities [2]. - The area has attracted major pharmaceutical companies, with recent approvals for new drugs such as the anti-flu drug and an antibody drug, indicating a robust pipeline of innovative products [2]. Semiconductor Industry - Jiangbei New Area hosts a significant number of semiconductor companies, including Nanjing University’s collaboration with Nanjing Jiangbei New Area to establish a leading photonic chip production line [3]. - Companies like Chipstar Technology have made strides in high-end chips, with their 7nm chip achieving significant market penetration [3]. - The area is recognized for its comprehensive semiconductor ecosystem, covering all aspects from design to manufacturing [3]. Educational and Research Institutions - The establishment of a technology transfer center in Jiangbei New Area has facilitated collaboration with 78 universities, resulting in numerous projects and a high concentration of talent [4][5]. - Nanjing University and Southeast University are key players in the area, contributing to a rich educational environment that supports innovation and research [4][5]. Innovation Ecosystem - Jiangbei New Area is focused on creating an integrated ecosystem that combines education, research, industry, and application, fostering a collaborative environment for innovation [5]. - The area has seen significant investment from venture capital, supporting the growth of local companies and enhancing the overall innovation landscape [5]. Community and Lifestyle - The demographic profile of Jiangbei New Area shows a high concentration of highly educated individuals, with over 30% of the local population holding advanced degrees [6]. - The community is actively engaged in various cultural and educational activities, contributing to a vibrant lifestyle that attracts young talent [6]. Infrastructure Development - The construction of Nanjing North Station as a major transportation hub is expected to enhance connectivity and attract resources, further supporting the innovation ecosystem in Jiangbei New Area [7]. Conclusion - Jiangbei New Area is positioned as a rising highland in Jiangsu, with a strong focus on biopharmaceuticals and semiconductors, supported by a robust educational framework and community engagement [8].